The Goodwin Paris Life Science team advised Genfit as (1) they entered into a licensing agreement with Genoscience Pharma for exclusive right to develop and commercialize the investigational treatment GNS561 in cholangiocarcinoma in the US, Canada and Europe (including the UK and Switzerland) and (2) as they took an equity stake in Genoscience through the subscription of new ordinary shares.
Genfit is a French late-stage biopharmaceutical company, listed on Nasdaq and Euronext, dedicated to improving the lives of patients with metabolic and chronic liver diseases.
Genoscience Pharma is a French clinical-stage biotechnology company developing novel lysomotropic therapeutics to establish a new standard of care against cancer, autoimmune and infectious diseases.
The Goodwin team consisted of Marie Fillon, Malcolm Bates and Louis de Chezelles on licensing aspects, Anne-Charlotte Rivière.